CompletedPhase 2NCT01575756
Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap
Studying Congenital fibrinogen deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Sigurd Knaub, PhDOctapharma
- Intervention
- Octafibrin(biological)
- Enrollment
- 22 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2013 – 2015
Study locations (10)
- University of Colorado Hemophilia & Thrombosis Center, Aurora, Colorado, United States
- Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
- Specialized Hospital for Active Treatment "Joan Pavel", Sofia, Bulgaria
- Department of Hematology St. John's Medical College Hospital, Bangalore, India
- Sahyadri Speciality Hospital, Prune, India
- Department of Hematology Christian Medical College, Vellore, India
- Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran
- Tehran University of Medical Sciences, Tehran, Iran
- Department of Hematology University Hospital, Zurich, Switzerland
- The Centre for Haemostatis and Thrombosis, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01575756 on ClinicalTrials.govOther trials for Congenital fibrinogen deficiency
Additional recruiting or active studies for the same condition.